Rheumocam

Meloxicam, the active ingredient in Rheumocam, is a nonsteroidal anti-inflammatory drug presented as a tablet for oral use. It reduces inflammation and pain associated with osteoarthritis, rheumatoid arthritis and other musculoskeletal conditions in adult patients, providing symptomatic relief and improved joint function.

GNH USA supplies Rheumocam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution originating from the European Union market. The company adheres to stringent quality standards and regulatory requirements.

Meloxicam is an NSAID indicated for several inflammatory joint disorders.

- Osteoarthritis: alleviates joint pain and stiffness, improving mobility. - Rheumatoid arthritis: reduces synovial inflammation and pain, helping preserve joint function. - Musculoskeletal pain: provides analgesic relief for acute or chronic soft‑tissue pain.

Meloxicam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Peripheral edema: swelling of the lower limbs. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Peptic ulcer disease or gastrointestinal bleeding. - Severe hepatic injury: jaundice or elevated liver enzymes. - Renal impairment: reduced urine output or increased creatinine. - Cardiovascular events: hypertension, myocardial infarction or stroke. - Anaphylactic reactions: difficulty breathing, swelling of face or throat.

Before prescribing meloxicam, clinicians should consider several safety precautions to minimise risk.

- Assess renal function: avoid use in patients with severe renal impairment. - Evaluate hepatic status: monitor liver enzymes in those with liver disease. - Cardiovascular risk: use cautiously in patients with hypertension, heart failure or prior thrombotic events. - Gastrointestinal history: avoid in individuals with active ulcer disease or a history of GI bleeding. - Concomitant NSAIDs or anticoagulants: increase bleeding risk, consider alternatives. - Store at room temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Meloxicam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): elevated bleeding potential.

Moderate Interactions (Monitor Closely): - ACE inhibitors or diuretics: may reduce renal function. - Lithium: meloxicam can raise lithium serum levels. - Methotrexate: potential for increased toxicity. - Corticosteroids: additive risk of GI ulceration.